Table 4.
Sensitivity | Specificity | PPV | NPV | |
---|---|---|---|---|
NSCLC | 87.12% (913/1048) | 64.61% (115/178) | 93.55% (913/976) | 46% (115/250) |
SCLC | 62.63% (57/91) | 99.5% (1129/1135) | 90.47% (57/63) | 97.08% (1129/1163) |
Adenocarcinoma | 68.1% (363/533) | 70.73% (145/205) | 85.82% (363/423) | 46.03% (145/315) |
Squamous carcinoma | 81.63% (120/147) | 65.93% (60/91) | 79.47% (120/151) | 68.97% (60/87) |
NSCLC versus Other 1; SCLC versus Other 2; adenocarcinoma versus Other 3; squamous carcinoma versus Other 4. Other 1 = SCLC and benign disease; Other 2 = NSCLC and benign disease; Other 3 = squamous carcinoma, large cell carcinoma, and benign disease; Other 4 = adenocarcinoma, large cell carcinoma, and benign disease.